Fenwick & West LLP represented Solta Medical, Inc. (NASDAQ: SLTM), a global leader in the medical aesthetics market providing innovative, safe, and effective solutions for patients that enhance and expand the practice of medical aesthetics for physicians in the public offering of 5,700,000 shares of its common stock at a price to the public of $2.65 per share. Net proceeds, after estimated underwriting discounts and estimated offering expenses, will be approximately $14 million. Solta Medical has granted the underwriters a 30-day option to purchase up to an additional 855,000 shares of common stock solely to cover over-allotments, if any. The offering is expected to close on or about August 7, 2012, subject to customary closing conditions. Canaccord Genuity served as sole book-running manager and Roth Capital Partners served as co-manager for the offering.
The Fenwick transaction team included corporate attorneys Dan Winnike, Niki Fang, Lara Anthony, Julia Forbess, and William Black. More information is available from Solta Medical's website: Solta Medical, Inc. Prices $15 Million Public Offering of Common Stock.